European Journal of Gynaecological Oncology (EJGO) is published by IMR Press from Volume 40 Issue 1 (2019). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on imrpress.com as a courtesy and upon agreement with S.O.G.
Cite this article
Adjuvant therapy for Stage IA uterine clear cell carcinoma with no myometrial invasion: a critical review of literature
1 Baskent University İstanbul Hospital, Department of Obstetrics and Gynecology, Istanbul, Turkey
2 Akdeniz University Hospital, Department of Obstetrics and Gynecology, Antalya, Turkey
3 Baskent University Ankara Hospital, Department of Obstetrics and Gynecology, Division og Gynecological Oncology, Ankara, Turkey
Eur. J. Gynaecol. Oncol. 2016, 37(1), 17–21; https://doi.org/10.12892/ejgo2775.2016
Published: 10 February 2016
Uterine clear cell carcinoma (UCC) is an aggressive variant of endometrial cancer. Comprehensive surgical staging is strongly recommended for these patients as an upstaging to Stage 3-4 occur in 35-50% of patients. Stage 1A (no myometrial invasion) according to FIGO 1988 staging system are seen very rarely in patients. In most of the studies, regarding adjuvant treatment, clear cell carcinoma were all evaluated with papillary serous carcinoma (PSC). Studies on clear cell histology are low in number and also a limited number of patients were included. Proportion of patients with complete surgical staging, number of lymph nodes excised, and rate of omentectomy were all heterogenous and were not presented uniformly in studies. There is no concensus regarding adjuvant treatment for Stage 1A patients. Some authors suggest only close observation. Vaginal brachytherapy is also strongly recommended in some studies of this review. Multi-institutional studies with homogenous patient characteristics with homogeneous surgery is warranted.
Uterine clear cell carcinoma
High grade endometrial cancer